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Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer 
characterized by a wide range of mutations and a dense 
stromal environment that makes the disease resistant to 
chemotherapy. This chemoresistance, coupled with late 
stage detection, often leads to fatal prognoses for patients 
diagnosed with PDAC. Little progress has been made in 
improving patient outcomes over the past 40 years and there 
is a need for innovative approaches to characterize molecular 
pathways involved in PDAC development.
The purpose of this study is to defi ne the role of a 
transmembrane receptor, PAR-1, in PDAC malignancy, 
to identify potential targets for therapeutic intervention. 
Previous studies have shown that the PAR-1 pathway 
is thrombin-activated, which provides a mechanism of 
experimental control over its activation. An assay to 
measure cell migration was used to quantify metastatic 
abilities of a representative PDAC cell line, KPC2, in the 
presence or absence of thrombin. The expected result was 
an increase in cell migration across the membrane following 
thrombin treatment, indicating increased metastatic ability. 
Initial results have confi rmed this hypothesis and provided 
evidence that the PAR-1 pathway is critical for pancreatic 
tumor development and metastasis.
As this research progresses, further work will be done to 
characterize downstream factors under the control of PAR-
1, which will contribute to the understanding of how this 
pathway induces tumor progression. Furthermore, PAR-1 
is a major component of the thrombosis and coagulation 
pathways, and RNA sequencing data will be used to identify 
cell types and factors critical to PAR-1-dependent immune 
evasion.
Research advisor Stephen Konieczny writes: “Pancreatic 
ductal adenocarcinoma is a lethal cancer with no 
satisfactory therapeutic strategies available to patients. 
Emily’s research has identifi ed the thrombin-PAR-1 
signaling pathway as critical to cell migration and cancer 
metastasis, providing important new insights in developing 
eff ective therapeutics that target this deadly disease.”
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Results of the transwell migration assay measuring metastatic ability of a PDAC cell line. The thrombin treated cells show significantly 
increased migration (indicated by the darker stain) when compared to the vehicle treated cells, *** p < 0.001.
